AGRX

Agile Therapeutics announced that it has reorganized and streamlined its executive leadership team to align with its business plan to promote Twirla transdermal system growth. As part of the changes, the company announced the appointment of Amy Welsh to chief commercial officer effective November 1. Additionally, James Tursi has informed the company that he will resign from the company's board of directors effective October 7. In addition to her current responsibilities leading the Twirla marketing team, Welsh, as chief commercial officer, will assume responsibility for all the company's commercial functions. Welsh joined the Company in May 2020 as VP, marketing.
https://www.tipranks.com/news/the-fly/agile-therapeutics-appoints-amy-welsh-to-chief-commercial-officer?utm_source=advfn.com&utm_medium=referral